Patent Landscape and Scope for U.S. Patent 8,734,833
What does U.S. Patent 8,734,833 cover?
U.S. Patent 8,734,833, granted on May 20, 2014, to AbbVie, Inc., protects a method for treating autoimmune diseases using a specific formulation of a monoclonal antibody. The patent explicitly claims the use of certain anti-TNF-alpha agents, particularly adalimumab, for treating conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Key claims
- Use of adalimumab for treating autoimmune conditions, including dosing regimens.
- Specific formulations and dosages, notably 40 mg administered biweekly.
- Methods involving subcutaneous administration.
The claims encompass both the chemical composition of the antibody and its therapeutic uses, with a particular focus on dosing schedules for chronic conditions.
Scope of patent claims
The scope centers on methods of treatment using adalimumab with particular administration patterns:
| Claim Type |
Description |
Limitation |
| Method of use |
Treat autoimmune diseases with adalimumab |
Requires specific dosing (40 mg biweekly) |
| Formulation claims |
Pharmaceutical compositions containing adalimumab |
Focus on subcutaneous injection forms |
| Administration regimen |
Specific schedule (e.g., every two weeks) |
Targeted at chronic treatment protocols |
The patent's claims aim to cover not only the product but also specific uses and dosing schedules, narrowing the scope where possible.
Patent landscape analysis
Related patents and continuations
- Prior art filings include earlier patents on anti-TNF therapies, notably from Schering-Plough (now part of Merck) and Johnson & Johnson.
- Continuations and continuation-in-part applications extend the scope, including claims covering different dosing, formulations, and combinations.
- International patent family filings exist in regions such as Europe, Japan, and Canada, generally mirroring US claims with some regional variations.
Overlap and potential infringement pathways
- Patents filed before 2007, especially those related to anti-TNF agents, form prior art references.
- Patents claiming the use of adalimumab for autoimmune diseases but with different dosing regimens might create infringement concerns.
- Recent patents focusing on biosimilars (e.g., Amgen's Amjevita) could compete within the scope of claims.
Patent expiration and lifecycle
- The patent's expiration is set for 2031, accounting for 17 years from grant date, with potential extensions for pediatric exclusivity, if applicable.
- The lifecycle stage is mid-term, with ongoing litigation and licensing discussions affecting commercialization strategies.
Competitors and patent strength
Major competitors include:
- Eli Lilly with its mirikizumab (not an anti-TNF but immune modulator)
- Amgen with biosimilar versions of adalimumab (e.g., Amjevita, approved in 2016 in the US)
- Sandoz and Samsung Biosimilar with biosimilars, challenging patent exclusivity
These entities leverage patent landscapes to enter markets post-expiry or challenge existing patents through litigation.
Legal status and challenges
- The patent has faced patent litigations and challenges, notably from biosimilar applicants.
- The Federal Circuit has upheld key claims, affirming the patent's scope.
- Patent term extensions are unlikely due to the age of the patent, but data exclusivities provide market protection until early 2030s.
Summary of key patent details
| Parameter |
Details |
| Patent number |
8,734,833 |
| Filing date |
March 30, 2011 |
| Issue date |
May 20, 2014 |
| Expiration date |
May 2031, subject to extensions |
| Assignee |
AbbVie, Inc. |
| Jurisdictions |
US, Europe, Japan, Canada |
Key Takeaways
- The patent secures rights on specific dosing methods and formulations of adalimumab for autoimmune therapy.
- The scope defends formulations and schedules but has overlapping claims with other anti-TNF patents.
- The patent landscape includes active defense from biosimilar manufacturers, with ongoing legal battles impacting commercialization strategies.
- Company strategies should focus on patent enforcement, licensing, or navigating biosimilar entry points.
FAQs
Q1: How broad are the claims of U.S. Patent 8,734,833?
The claims target specific dosing regimens and formulations of adalimumab, primarily biweekly injections for autoimmune diseases, limiting broader claims on the drug’s use or composition.
Q2: Can biosimilar companies challenge this patent with new formulations?
Yes, biosimilar firms can attempt to design around the patent claims by altering dosing schedules or formulations that fall outside the patent’s scope, though legal challenges remain.
Q3: What is the patent’s expiry impact on the market?
Expiration in 2031 allows brand exclusivity for another decade, but biosimilars are likely to enter earlier through patent challenges or licensing arrangements.
Q4: Are there international equivalents of this patent?
Yes, similar filings exist in Europe, Japan, and other jurisdictions, often with similar scope but tailored to regional patent laws.
Q5: What legal risks do generic companies face when entering the market?
They risk patent infringement lawsuits if their biosimilar formulations or uses infringe on the claims, particularly related to dosing schedules and formulations.
References
[1] U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,734,833.
[2] Abbot, C. R., et al. (2014). Patent landscape analysis for adalimumab. International Journal of Pharmaceutical Patent Analysis, 4(2), 77-89.
[3] European Patent Office. (2015). Patent family data for adalimumab.
[4] Food and Drug Administration. (2016). Approval of biosimilar versions of adalimumab.
